18
I LISI FINANCIALREPORT2013
FINANCIALSITUATION
2
1.3
|
LISI MEDICAL
€64.1m
SALESREVENUE
474
STAFF
€3.1m
INVESTMENTS
Activity
Medical implant andauxiliary
partssub-contractor.
Flagshipproducts
Jointreconstruction:
Orthopedicreconstruction
implantsand instruments (hip,
shoulder,knee).
Spine,traumaanddental:
Orthopedic (foot,hand,
shoulder), trauma, spinal,
maxillofacialanddental
implantsand instruments.
Customers
AceSurgical;
AlphatecSpine;
Biomet3i;
BiosenseWebster;
LDRMedical;
Medacta;
Medicrea;
Newdeal Integra;
SerfDedienne;
Smith&Nephew;
Spineway;
Stryker;
Tornier;
Zimmer;
Competitors
Accelent;
Greatbatch;
IMDS /C5
Marle;
Norwood;
Orchid /Sandvik;
Paragon;
Symmetry;
Teleflex /Tecomet;
2
| GROUPACTIVITYFORTHEFINANCIALYEAR,ANDOUTLOOKFORTHECOMINGYEAR
2.1
|
LISI CONSOLIDATED
2013hasbeenanewyearof improvedprofitability fortheLISIGroup.
Consolidated sales revenues of €1,149m were up nominally 6.3% and
up 7.3%at a constant consolidation scopeand exchange rates,which is
reflected inthe followingdevelopments incurrentexchangerates:
n
the confirmed dynamism of the LISI AEROSPACE division (up 12.2%),
whichhasachievedhistoricallyhigh levelsboth inaerospace fasteners
andstructuralcomponents,
n
thesolidperformanceofLISIAUTOMOTIVE (-1.0%),
n
the gradual recovery of LISI MEDICAL (down 1.1% as comparedwith
down12.1% in2012).
CommentsregardingQ4business
LISI
Consolidated
ofwhich
LISI AEROSPACE
ofwhich
LISI AUTOMOTIVE
ofwhich
LISI MEDICAL
Q1
298.6
172.9
110.2
16.0
Q2
296.2
169.8
110.2
16.6
Q3
277.0
160.1
100.6
16.5
Q4
277.2
161.1
101.3
15.1
2013
1,149.0
663.9
422.2
64.1
Ananalysisof the increaseof 5.2% in consolidated sales revenues in the
fourthquarterascomparedwith thepreviousyear (€263.5m),highlights
the followingdifferencesbetweenthedivisions:
n
LISIAEROSPACE saw itsgrowth rate slowdown in the secondhalf (up
10.2% inQ3,up5.2% inQ4,asagainstup16.9% forH1).
n
On theotherhand, afteradifficult start to theyear, LISIAUTOMOTIVE
hasgraduallyreestablished itselftoendtheyearup4.4% inQ4.
n
LISIMEDICALhasalsopostedanet improvement inQ4 (up9.4%).
